Artivion (AORT) 10-Q 29 Apr 16 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 22, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Central Index Key	784,199
Entity Registrant Name	CRYOLIFE INC
Trading Symbol	cry
Entity Common Stock, Shares Outstanding		32,613,669

Consolidated Statements Of Oper

Consolidated Statements Of Operations And Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Products	$ 27,018	$ 19,391
Preservation services	15,998	14,440
Total revenues	43,016	33,831
Cost of products and preservation services:
Products	7,003	5,033
Preservation services	8,392	9,131
Total cost of products and preservation services	15,395	14,164
Gross margin	27,621	19,667
Operating expenses:
General, administrative, and marketing	26,274	18,969
Research and development	2,609	2,252
Total operating expenses	28,883	21,221
Gain from sale of business components	(7,915)
Operating income (loss)	6,653	(1,554)
Interest expense	717	30
Interest income	(12)	(3)
Other (income) expense, net	(109)	192
Income (loss) before income taxes	6,057	(1,773)
Income tax expense (benefit)	3,516	(1,499)
Net income (loss)	$ 2,541	$ (274)
Income (loss) per common share:
Basic	$ 0.08	$ (0.01)
Diluted	$ 0.08	(0.01)
Dividends declared per common share		$ 0.03
Weighted-average common shares outstanding:
Basic	31,029	27,523
Diluted	31,771	27,523
Other comprehensive loss	$ (96)	$ (117)
Comprehensive income (loss)	$ 2,445	$ (391)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 44,827	$ 37,588
Restricted securities	812	830
Receivables, net	29,428	26,672
Inventories	25,287	14,643
Deferred preservation costs	26,002	24,741
Prepaid expenses and other	2,880	5,189
Total current assets	129,236	109,663
Property and equipment, net	16,497	11,484
Restricted cash		5,000
Goodwill	76,833	11,365
Patents, net	1,119	1,417
Trademarks and other intangibles, net	67,055	18,480
Deferred income taxes	1,550	18,188
Other	4,867	5,582
Total assets	297,157	181,179
Current liabilities:
Accounts payable	5,553	4,648
Accrued compensation	6,663	6,335
Accrued procurement fees	4,427	4,445
Accrued expenses and other	6,869	4,177
Current portion of long-term debt	1,330
Total current liabilities	24,842	19,605
Long-term debt	71,241
Other	6,914	6,323
Total liabilities	$ 102,997	$ 25,928
Commitments and contingencies
Shareholders' equity:
Preferred stock
Common stock (issued shares of 33,944 in 2016 and 29,766 in 2015)	$ 339	$ 298
Additional paid-in capital	180,217	142,888
Retained earnings	25,906	23,365
Accumulated other comprehensive loss	(172)	(76)
Treasury stock at cost (shares of 1,356 in 2016 and 1,265 in 2015)	(12,130)	(11,224)
Total shareholders' equity	194,160	155,251
Total liabilities and shareholders' equity	$ 297,157	$ 181,179

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares shares in Thousands	Mar. 31, 2016	Dec. 31, 2015
Consolidated Balance Sheets [Abstract]
Common stock, shares issued	33,944	29,766
Treasury stock at cost, shares	1,356	1,265

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net cash flows from operating activities:
Net income (loss)	$ 2,541	$ (274)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Gain from sale of business components	(7,915)
Depreciation and amortization	1,929	1,555
Non-cash compensation	1,413	1,137
Other non-cash adjustments to income	791	594
Changes in operating assets and liabilities:
Receivables	4,249	1,217
Inventories and deferred preservation costs	(2,760)	(897)
Prepaid expenses and other assets	1,423	272
Accounts payable, accrued expenses, and other liabilities	(261)	(2,306)
Net cash flows provided by operating activities	1,410	1,298
Net cash flows from investing activities:
Acquisition of On-X, net of cash acquired	(91,152)
Proceeds from sale of business components	19,795
Decrease in restricted cash	5,000
Capital expenditures	(820)	(1,055)
Other	22	(495)
Net cash flows used in investing activities	(67,155)	(1,550)
Net cash flows from financing activities:
Proceeds from issuance of term loan	75,000
Payment of debt issuance costs	(2,289)
Proceeds from exercise of stock options and issuance of common stock	736	683
Cash dividends paid		(850)
Other	(335)	(449)
Net cash flows provided by (used in) financing activities	73,112	(616)
Effect of exchange rate changes on cash	(128)	(94)
Increase (decrease) in cash and cash equivalents	7,239	(962)
Cash and cash equivalents, beginning of period	37,588	33,375
Cash and cash equivalents, end of period	$ 44,827	$ 32,413

Basis Of Presentation

Basis Of Presentation	3 Months Ended
	Mar. 31, 2016
Basis Of Presentation [Abstract]
Basis Of Presentation	1. Basis of Presentation  The accompanying summary consolidated financial statements include the accounts of CryoLife, Inc. and its subsidiaries (“CryoLife,” the “Company,” “we,” or “us”) . All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying Summary Consolidated Balance Sheet as of December 31, 2015 has been derived from audited financial statements. The accompanying unaudited summary consolidated financial statements as of, and for the three months ended , March 31, 2016 and 2015 have been prepared in accordance with (i) accounting principles generally accepted in the U.S. for interim financial information and (ii) the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, such statements do not include all of the information and disclosures required by accounting principles generally accepted in the U.S. for a complete presentation of financial statements. In the opinion of management, all adjustments (including those of a normal, recurring nature) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016 . These summary consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in CryoLife’s Annual Report on Form 10-K for the year ended December 31, 2015 . 

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2016
Financial Instruments [Abstract]
Financial Instruments	2. Financial Instruments The following is a summary of the Company’s financial instruments measured at fair value (in thousands):     March 31, 2016 Level 1 Level 2 Level 3 Total  Cash equivalents:  Money market funds $ 714 $ -- $ -- $ 714  Restricted securities:  Money market funds 812 -- -- 812  Total assets $ 1,526 $ -- $ -- $ 1,526      December 31, 2015 Level 1 Level 2 Level 3 Total  Cash equivalents:  Money market funds $ 549 $ -- $ -- $ 549  Restricted securities:  Money market funds 830 -- -- 830  Total assets $ 1,379 $ -- $ -- $ 1,379  The Company used prices quoted from its investment management companies to determine the Level 1 valuation of its investments in money market funds.

Cash Equivalents And Restricted

Cash Equivalents And Restricted Cash And Securities	3 Months Ended
	Mar. 31, 2016
Cash Equivalents And Restricted Cash And Securities [Abstract]
Cash Equivalents And Restricted Cash And Securities	3. Cash Equivalents and Restricted Cash and Securities The following is a summary of cash equivalents and restricted cash and securities (in thousands):    Unrealized Estimated  Holding Market  March 31, 2016 Cost Basis Gains Value  Cash equivalents:  Money market funds $ 714 $ -- $ 714  Restricted cash and securities:  Money market funds 812 -- 812   Unrealized Estimated  Holding Market  December 31, 2015 Cost Basis Gains Value  Cash equivalents:  Money market funds $ 549 $ -- $ 549  Restricted cash and securities:  Cash 5,000 -- 5,000  Money market funds 830 -- 830 As of March 31, 2016 and December 31, 2015 $ 812,000 and $ 830,000 , respectively, of the Company’s money market funds were designated as short-term restricted securities due to a contractual commitment to hold the securities as pledged collateral relating primarily to international tax obligations. As of December 31, 2015 $ 5.0 million of the Company’s cash was designated as long-term restricted cash due to a financial covenant requirement under the Company’s debt agreement. As of March 31, 2016 the Company no longer had a financial covenant requirement for restricted cash under the Company’s amended debt agreement. See further discussion of the Company’s debt agreements in Note 11 .  There were no gross realized gains or losses on cash equivalents in the three months ended March 31, 2016 and 2015 . As of March 31, 2016 $241,000 of the Company’s restricted securities had a maturity date within three months and $571,000 had a maturity date between three months and one year. As of December 31, 2015 $595,000 of the Company’s restricted securities had a maturity date within three months and $235,000 had a maturity date between three months and one year. As of December 31, 2015 $ 5.0 million of the Company’s long-term restricted cash had no maturity date.

Acquisition Of On-X Life Techno

Acquisition Of On-X Life Technologies	3 Months Ended
	Mar. 31, 2016
Acquisition of On-X Life Technologies [Abstract]
Acquisition Of On-X Life Technologies	4. Acquisition of On-X Life Technologies  Overview  On December 22, 2015 the Company entered into the Agreement and Plan of Merger (“On-X Agreement”) to acquire On-X Life Technologies Holdings, Inc. (“On-X”) , an Austin , Texas-based, privately held mechanical heart valve company, for approximately $130.0 million, subject to certain adjustments. The transaction closed on January 20, 2016 , and On-X is being operated as a wholly-owned subsidiary of CryoLife.  The On-X catalogue of products includes the On-X prosthetic aortic and mitral heart valve s and the On-X ascending aortic prosthesis (“AAP”). On-X also distributes CarbonAid CO 2 diffusion catheters, manufactures Chord-X ePTFE sutures for mitral chordal replacement, and offers pyrolytic carbon coating services to other medical device manufacturers. CryoLife believes that the On-X products will fit well into its product portfolio of medical devices for cardiac surgery and believes there is a significant opportunity for CryoLife’s sales team to leverage their strong relationships with cardiac surgeons to introduce and to expand utilization of the On-X valve in the U.S. and internationally.  Accounting for the Transaction  The purchase price of the transaction totaled approximately $128.2 million, consisting of cash of $93.6 million and 3,703,699 shares of CryoLife common stock, with a value of $34.6 million as determined on the date of the closing. This purchase price is subject to several potential adjustments, which have not yet been finalized. The Company’s preliminary allocation of the $128.2 million purchase price to On-X’s tangible and identifiable intangible assets acquired and liabilities assumed, based on their estimated fair values as of January 20, 2016, is included in the table below. Goodwill is recorded based on the amount by which the purchase price exceeds the fair value of the net assets acquired and is not deductible for tax purposes.  The preliminary purchase price allocation as of January 20, 2016 is as follows (in thousands):     Opening  Balance Sheet  Cash and cash equivalents $ 2,472  Receivables 6,265  Inventories 13,033  Intangible assets 53,950  Goodwill 66,768  Other assets 6,184  Liabilities assumed (20,455)  Total purchase price $ 128,217  The preliminary allocation of the purchase price is based on preliminary valuations performed to determine the fair value of such assets as of the acquisition date. As the Company’s acquisition accounting is incomplete, t he Company may adjust the amounts recorded as of March 31, 2016 to reflect any revised evaluations of the assets acquired or liabilities assumed. Goodwill from this transaction will be allocated to the Company’s medical devices segment. CryoLife incurred transaction and integration costs of $5.5 million for the three months ended March 31, 2016 related to the acquisition, which include, among other costs, expenses related to the termination of international and domestic distribution agreements. These costs were expensed as incurred and were primarily recorded as general, administrative, and marketing expenses on the Company’s Summary Consolidated Statements of Operations and Comprehensive Income.  Pro Forma Results The Company’s unaudited pro forma results of operations for the quarter ended March 31, 2016 and 2015 assuming the On-X acquisition had occurred as of January 1, 2015 are presented for comparative purposes below. These amounts are based on available information of the results of operations of On-X prior to the acquisition date and are not necessarily indicative of what the results of operations would have been had the acquisition been completed on January 1, 2015. The pro forma adjustments related to the acquisition of On-X are based on a preliminary purchase price allocation. Differences between the preliminary and final purchase price allocation could have an impact on the pro forma financial information presented below and that impact could be material. This unaudited pro forma information does not project operating results post acquisition.  This preliminary pro forma information is as follows (in thousands, except per share amounts):     Three Months Ended  March 31,  2016 2015  Total revenues $ 44,643 $ 41,612  Net income 5,661 (12,447)   Pro forma income per common share - basic $ 0.17 $ (0.39)  Pro forma income per common share - diluted $ 0.17 $ (0.39)  Pro forma net income was calculated using a tax rate of approximately 38% .

Sales Of Business Components

Sales Of Business Components	3 Months Ended
	Mar. 31, 2016
Sales Of Business Components [Abstract]
Sales Of Business Components	5. Sales of Business Components  Divestiture of the HeRO Graft Product Line  On February 3, 2016 the Company sold its Hemodialysis Reliable Outflow Graft (“HeRO ® Graft”) product line to Merit Medical Systems, Inc. (“Merit”) for $18.5 million in cash (“HeRO Sale”) , of which $17.8 million had been received by March 31, 2016 . Under terms of the agreement, Merit acquired the HeRO Graft product line, including worldwide marketing rights, customer relationships, intellectual property, inventory, and certain property and equipment. The Company will continue to manufacture the HeRO Graft for up to six months under a transition supply agreement, after which Merit will be responsible for manufacturing. Sales prices under the transition supply agreement are at lower average prices than the Company’s previous sales to hospitals at end-user prices. The disposal of the HeRO Graft is part of a strategic shift of the Company’s focus to selling its expanded portfolio of cardiac surgery products, including the On-X heart valve. The HeRO Graft product line was included as part of the Company’s Medical Devices segment. The Company recorded a pre-tax gain of approximately $8.8 million on the HeRO sale.  Divestiture of the ProCol Product Line  On March 18, 2016 the Company sold its ProCol ® Vascular Bioprosthesis (“ProCol”) distribution rights and purchase option to LeMaitre Vascular, Inc. (“LeMaitre”) for $2.0 million in cash (“ProCol Sale”) , all of which was received by March 31, 2016 . Under terms of the agreement, LeMaitre acquired the ProCol related assets, including inventory, customer lists, related marketing assets, and the Company’s purchase option to acquire ProCol. LeMaitre exercised the option to acquire ProCol from Hancock Jaffe Laboratories. The disposal of ProCol is part of a strategic shift of the Company’s focus to selling its expanded portfolio of cardiac surgery products, including the On-X heart valve. The ProCol product was included as part of the Company’s Medical Devices segment. The Company recorded a pre-tax loss of approximately $845,000 on the ProCol sale.  In 2014 CryoLife acquired the exclusive worldwide distribution rights to ProCol from Hancock Jaffe Laboratories, Inc. (“Hancock Jaffe”). In accordance with the terms of the a greement with H ancock J affe , CryoLife made payments to Hancock Jaffe of $1.7 million during 2014 and $576,000 in January 2015. In exchange for these payments, CryoLife obtained the right to receive a designated amount of ProCol inventory for resale, portion s of which the Company received in 2014, 2015, and 2016. CryoLife made additional payments of $1.2 million in the aggregate during 2015 and the first quarter of 2016. As of March 31, 2016 C ryoLife had made a total of $3.4 million in payments to Hancock Jaffe and had received $1.7 million in inventory. The remaining $1.7 million in prepayments were settled as part of the ProCol Sale.  Disclosure of the HeRO Sale and the ProCol Sale  FASB ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, defines the criteria for reporting discontinued operations and requires additional disclosures about discontinued operations. The standard requires that an entity report as a discontinued operation only a disposal that represents a strategic shift in operations that has a major effect on the Company’s operations and financial results.  In the first quarter of 2016 the Company completed the HeRO Sale and the ProCol Sale. The Company received cash for these transactions and recorded the results of these sales in the three months ended March 31, 2016 . Therefore , as of March 31, 2016 both transactions meet the disposed of by sale criteria under discontinued operations.  The Company then evaluated the HeRO Sale and the ProCol Sale to determine whether these disposals represent a strategic shift that has, or will have, a major effect on the Company’s financial position, results of operations, or cash flows. T he Company evaluated the impact of the HeRO Sale and the ProCol Sale on the Company’s business. As the HeRO Graft and ProCol product lines combined represented less than 10% of total Company revenues for the year ended December 31, 2015 and the Company’s total assets as of December 31, 2015, the Company believes that these transactions did not have a major effect on the Company’s operations and financial condition, either individually or in the aggregate, and therefore the Company did not disclose these transactions as discontinued operations. The combined net gain from the HeRO Sale and ProCol sale was therefore reported as gain from sale of business components on the Company’s Summary Consolidated Statements of Operations and Comprehensive Income. 

PhotoFix Distribution Agreement

PhotoFix Distribution Agreement	3 Months Ended
	Mar. 31, 2016
PhotoFix Distribution Agreement [Abstract]
PhotoFix Distribution Agreement	6. PhotoFix Distribution Agreement Overview  In 2014 CryoLife entered into an exclusive supply and distribution agreement with Genesee Biomedical, Inc. (“GBI”) to acquire the distribution rights to PhotoFix TM , a bovine pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. PhotoFix has received U.S. Food and Drug Administration (“ FDA ”) 510(k) clearance and is indicated for use in intracardiac repair, including ventricular repair and atrial repair, great vessel repair and suture line buttressing, and pericardial closure. In January 2015 the Company received its initial shipments and launched its distribution of PhotoFix.  The agreement between CryoLife and GBI (the “GBI Agreement”) ha d an initial five -year term and was renewable for two one -year periods at CryoLife’s option. Under the terms of the GBI Agreement, CryoLife purchas ed PhotoFix inventory for resale at an agreed upon transfer price and ha d the option, which became effective in March 2015, to acquire the PhotoFix product line from GBI.  Acquisition  On April 13, 2016 the Company exercised its right to acquire the PhotoFix technology from GBI for $2.3 million. The Company anticipates allocating the majority of the purchase price to intangible assets. GBI will continue to manufacture PhotoFix until the Company is able to establish manufacturing operations. 

Medafor Matters

Medafor Matters	3 Months Ended
	Mar. 31, 2016
Medafor Matters [Abstract]
Medafor Matters	7. Medafor Matters Investment in Medafor Common Stock  In 2009 and 2010 CryoLife purchased shares of common stock in Medafor, Inc., (“Medafor”) a developer and supplier of plant based hemostatic agents. The Company initially recorded its investment using the cost method as a long-term asset, investment in equity securities, on the Company’s Summary Consolidated Balance Sheets.  On October 1, 2013 C.R. Bard, Inc. (“Bard”), and its subsidiaries completed its acquisition of all outstanding shares of Medafor common stock. The Company received payments of approximately $15.4 million in 2013, $530,000 in 2014, and $891,000 in April 2015 for its 2.4 million shares of Medafor common stock . The final release of transaction consideration from escrow is expected to be received in October 2017 and is expected to be nominal. This subsequent payment will be recorded as an additional gain if, and when, received by the Company.  Legal Action  In April 2014 CryoLife filed a declaratory judgment lawsuit against Bard, and its subsidiaries Davol, Inc. (“Davol”) and Medafor (collectively, “Defendants”), in the District Court for the District of Delaware (the “Court”) . CryoLife requested that the Court declare that CryoLife’s manufacture, use, offer for sale, and sale of PerClot in the U.S. does not, and would not, infringe Bard’s U.S. Patent No. 6,060,461 (the “‘461 Patent”). In addition, CryoLife requested that the Court declare that the claims of the ‘461 Patent are invalid. CryoLife also requested injunctive relief and an award of attorneys’ fees.  The lawsuit against the Defendants followed the receipt by CryoLife of a letter from Medafor in September 2012 stating that PerClot, when introduced in the U.S., would infringe the ‘461 Patent when used in accordance with the method published in CryoLife’s literature and with the instructions for use. CryoLife received FDA 510(k) clearance for the sale of PerClot Topical in April 2014 and began distributing this product in August 2014. PerClot Topical is a version of the Company’s PerClot product, which was manufactured by the Company at its headquarters and labeled for use in certain topical indications. CryoLife also received investigational device exemption approval in March 2014 to begin clinical trials for PerClot in certain surgical indications.  In August 2014 Medafor filed a counterclaim against CryoLife for infringement of the ‘461 Patent. In September 2014 Medafor filed a motion for a preliminary injunction, asking the Court to enjoin CryoLife’s marketing and sale of PerClot in the U.S. In March 2015 the Court ruled that CryoLife’s declaratory judgment lawsuit against Medafor may proceed but dismissed Bard and Davol from the lawsuit. The Court also granted Medafor’s motion for a preliminary injunction, which prohibited CryoLife from marketing, selling, and distributing PerClot in the U.S. while the litigation proceeded. In March 2015 CryoLife ceased all marketing, sales, and distribution of PerClot in the U.S., including PerClot Topical, in accordance with the Court’s order. In April 2015 CryoLife appealed the Court’s ruling on the preliminary injunction motion to the U.S. Court of Appeals for the Federal Circuit. CryoLife dismissed this appeal in June 2015. On November 18, 2015, the lawsuit was resolved by entry by the Court of the Parties’ Joint Stipulation for Dismissal, which resulted in the dismissal with prejudice of all parties’ claims and counterclaims in the lawsuit, the continuation of the preliminary injunction prohibiting CryoLife from marketing, selling and distributing PerClot in the U.S. until expiration of the ‘461 Patent on February 8, 2019, each party bearing its own attorneys’ fees and costs associated with the lawsuit, and the continuation of the Court’s jurisdiction over the parties to enforce the resolution. 

Inventories And Deferred Preser

Inventories And Deferred Preservation Costs	3 Months Ended
	Mar. 31, 2016
Inventories And Deferred Preservation Costs [Abstract]
Inventories And Deferred Preservation Costs	8. Inventories and Deferred Preservation Costs Inventories at March 31, 2016 and December 31, 2015 are comprised of the following (in thousands):    March 31, December 31,  2016 2015  Raw materials and supplies $ 8,868 $ 8,590  Work-in-process 2,610 633  Finished goods 13,809 5,420  Total inventories $ 25,287 $ 14,643  Deferred preservation costs at March 31, 2016 and December 31, 2015 are comprised of the following (in thousands):    March 31, December 31,  2016 2015  Cardiac tissues $ 13,065 $ 11,722  Vascular tissues 12,937 13,019  Total deferred preservation costs $ 26,002 $ 24,741  The Company maintains consignment inventory of its On-X heart valves at domestic and international hospital locations to facilitate usage. The Company retains title to this consignment inventory until the valve is implanted, at which time the Company invoices the hospital. As of March 31, 2016 the Company had $4.7 million in consignment inventory. Approximately 85% of the Company’s consignment inventory is domestic and 15% is foreign.

Goodwill And Other Intangible A

Goodwill And Other Intangible Assets	3 Months Ended
	Mar. 31, 2016
Goodwill And Other Intangible Assets [Abstract]
Goodwill And Other Intangible Assets	9. Goodwill and Other Intangible Assets Indefinite Lived Intangible Assets As of March 31, 2016 and December 31, 2015 the carrying values of the Company’s indefinite lived intangible assets are as follows (in thousands):     March 31, December 31,  2016 2015  Goodwill $ 76,833 $ 11,365  Procurement contracts and agreements 2,013 2,013  Trademarks 839 860  Based on its experience with similar agreements, the Company believes that its acquired procurement contracts and agreements have indefinite useful lives, as the Company expects to continue to renew these contracts for the foreseeable future. The Company believes that its trademarks have indefinite useful lives as the Company currently anticipates that these trademarks will contribute to cash flows of the Company indefinitely.  As of March 31, 2016 and December 31, 2015 the value of the Company’s goodwill, all of which is related to its Medical Devices segment, is as follows (in thousands):     Medical Devices Segment  Balance as of December 31, 2015 $ 11,365  Goodwill from On-X acquisition 66,768  Goodwill allocated to sale of HeRO Graft product line (1,200)  Goodwill allocated to sale of ProCol distribution rights and purchase option (100)  Balance as of March 31, 2016 $ 76,833  Definite Lived Intangible Assets As of March 31, 2016 and December 31, 2015 the gross carrying values, accumulated amortization, and approximate amortization period of the Company’s definite lived intangible assets are as follows (in thousands):     Gross Carrying Accumulated Amortization  March 31, 2016 Value Amortization Period  Acquired technology $ 36,410 $ 4,296 11 – 22 Years  Customer lists and relationships 29,140 1,092 13 – 22 Years  Distribution and manufacturing rights and know-how 4,059 1,317 11 – 15 Years  Patents 3,775 2,656 17 Years  Non-compete agreement 381 352 10 Years  Other 1,605 335 3 – 5 Years   Gross Carrying Accumulated Amortization  December 31, 2015 Value Amortization Period  Acquired technology $ 14,020 $ 4,954 11 – 16 Years  Patents 4,081 2,664 17 Years  Distribution and manufacturing rights and know-how 4,059 1,245 11 – 15 Years  Customer lists and relationships 3,370 1,054 13 – 17 Years  Non-compete agreement 381 343 10 Years  Other 1,583 210 3 – 5 Years  The increase in gross carrying value of the Company’s intangible assets as of March 31, 2016 when compared to December 31, 2015 is primarily due to the Company’s acquisition of On-X on January 20, 2016 , partially offset by reductions due to the HeRO Sale . See Note 4 for further discussion of the acquisition of On-X and Note 5 for further discussion of the HeRO Sale .  Amortization Expense  The following is a summary of amortization expense as recorded in general, administrative, and marketing expenses on the Company’s Summary Consolidated Statement of Operations and Comprehensive Income (in thousands):    Three Months Ended  March 31,  2016 2015  Amortization expense $ 962 $ 515   As of March 31, 2016 scheduled amortization of intangible assets for the next five years is as follows (in thousands):    Remainder  of 2016 2017 2018 2019 2020 2021  Amortization expense $ 3,399 $ 4,487 $ 4,369 $ 3,984 $ 3,812 $ 3,789

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Taxes [Abstract]
Income Taxes	10. Income Taxes Income Tax Expense  The Company’s effective income tax rate was approximately 58% for the three months ended March 31, 2016 , as compared to 85% for the three months ended March 31, 2015 . The Company’s income tax rate for the three months ended March 31, 2016 was unfavorably impacted by the tax treatment of certain expenses related to the On-X acquisition and by book-to-tax basis differences related to the HeRO Sale.  The Company’s income tax rate for the three months ended March 31, 2015 was unfavorably affected by the absence of the domestic production activities deduction, as the Company did not anticipate being eligible for this deduction in 2015, and by other permanent book/tax differences, which were expected to have a proportionally larger impact in 2015 than in the current year when compared to the Company’s estimates of pretax book income. The Company’s income tax rate for the three months ended March 31, 2015 did not include an anticipated benefit from the research and development tax credit, as this credit had not yet been enacted at that time.  Deferred Income Taxes  Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and tax return purposes. The Company generates deferred tax assets primarily as a result of book write-downs, reserves, or impairments which are not immediately deductible for tax return purposes. The Company acquired deferred tax assets, primarily net operating loss carryforwards, from its acquisitions of On-X, Hemosphere, and Cardiogenesis Corporation. The Company currently estimates that a portion of its state net operating loss carryforwards will not be recoverable and has, therefore, recorded a valuation allowance against these state net operating loss carryforwards.  As of March 31, 2016 the Company maintained a total of $ 2.3 million in valuation allowances against deferred tax assets, related to state net operating loss carryforwards, and a net deferred tax asset of $ 1.6 million. As of December 31, 2015 the Company had a total of $ 2.1 million in valuation allowances against deferred tax assets and a net deferred tax asset of $ 18.2 million.

Debt

Debt	3 Months Ended
	Mar. 31, 2016
Debt [Abstract]
Debt	11. Debt GE Credit Agreement On September 26, 2014 CryoLife amended and restated its credit agreement with GE Capital, extending the expiration date and amending other terms, which are discussed further below. CryoLife’s second amended and restated credit agreement with GE Capital (the “GE Credit Agreement”) provided revolving credit for working capital, permitted acquisitions, and general corporate purposes . The GE Credit Agreement had aggregate commitments of $20.0 million for revolving loans, including swing loans, subject to a sublimit, and letters of credit, and was due to mature on September 26, 2019 .  Amounts borrowed under the GE Credit Agreement were secured by substantially all of the tangible and intangible assets of CryoLife and its subsidiaries. Commitment fees were paid based on the unused portion of the facility. As of December 31, 2015 the aggregate interest rate was 4.75% . As of December 31, 2015 the outstanding balance of the GE Credit Agreement was zero , and the remaining availability was $20.0 million.  The GE Credit Agreement placed limitations on the amount that the Company may borrow and include d various affirmative and negative covenants, including financial covenants such as a requirement that CryoLife (i) not exceed a defined leverage ratio and (ii) maintain minimum earnings subject to defined adjustments as of specified dates. The agreement also (i) limited the payment of cash dividends, up to specified maximums and subject to satisfaction of specified conditions, (ii) required that, after giving effect to a stock repurchase, the Company maintain liquidity, as defined within the agreement, of at least $ 20.0 million, (iii) limited acquisitions or mergers except for certain permitted acquisitions, (iv) set specified limits on the amount the Company can pay to purchase or redeem CryoLife common stock pursuant to a stock repurchase program and to fund estimated tax liabilities incurred by officers, directors, and employees as a result of awards of stock or stock equivalents, and (v) included customary conditions on incurring new indebtedness.  As required under the terms of the GE Credit Agreement, the Company maintained cash and cash equivalents of at least $ 5.0 million in accounts in which GE Capital ha d a first priority perfected lien. These amounts were recorded as long-term restricted cash as of December 31, 2015 on the Company’s Summary Consolidated Balance Sheets, as they were restricted for the term of the GE Credit Agreement.  Amended Debt Agreement  In connection with the closing of the On-X acquisition, discussed above in Note 4 , on January 20, 2016 the Company and certain of its subsidiaries entered into the Third Amended and Restated Credit Agreement (“Amended Debt Agreement”) with Capital One, National Association , who acquired GE Capital’s Healthcare Financial Services lending business in late 2015 ; Healthcare Financial Solutions, LLC; Fifth Third Bank; and Citizens Bank, National Association, collectively the (“Lending Parties”). The Amended Debt Agreement amended and restated the GE Credit Agreement discussed above and provides the Company with a senior secured credit facility in an aggregate principal amount of $95 million, which includes a $75 million term loan and a $20 million revolving credit facility (including a $4 million letter of credit sub-facility and a $3 million swing-line sub-facility). The $75 million term loan was used to finance, in part, the acquisition of On-X and will mature on January 20, 2021 .  The Company and its domestic subsidiaries, subject to certain exceptions and exclusions, have guaranteed the obligations of the Amended Debt Agreement. Borrowings under the Amended Debt Agreement are secured by substantially all of the Company’s real and personal property.  The loans under the Amended Debt Agreement (other than the swing-line loans) bear interest, at the Company’s option, at either a floating rate equal to the base rate , as defined in the Amended Debt Agreement, plus a margin of between 1.75% and 2.75% , depending on the Company’s consolidated leverage ratio , or a per annum rate equal to LIBOR plus a margin of between 2.75% and 3.75% , depending on the Company’s consolidated leverage ratio. As of March 31, 2016 the aggregate interest rate was 3.93% . Swing-line loans shall bear interest at a floating rate equal to the base rate plus a margin of between 1.75% and 2.75% , depending on the Company’s consolidated leverage ratio. The Company is obligated to pay an unused commitment fee equal to 0.50% of the un-utilized portion of the revolving loans. In addition, the Company is also obligated to pay other customary fees for a credit facility of this size and type. If and w hile a payment event of default exists, the Company is obligated to pay a per annum default rate of interest of 2.00% above the applicable interest rate on the past due principal amount of the loans outstanding. If and w hile a bankruptcy or insolvency event of default exists, the Company is obligated to pay a per annum default rate of interest of 2.00% above the applicable interest rate on all loans outstanding.  Interest is due and payable , with respect to base rate loans , on a quarterly basis . Interest is due and payable , with respect to LIBOR loans , on the last day of the applicable interest period , if the interest period is shorter than six months, or on the last day of each three month interval, if the interest period is six months or greater .  The Amended Debt Agreement prohibits the Company from exceeding a maximum consolidated leverage ratio during the term of the Amended Debt Agreement and requires the Company to maintain a minimum interest coverage ratio. In addition, the Amended Debt Agreement contains certain customary affirmative and negative covenants, including covenants that limit the ability of the Company and its subsidiaries which are parties to the loan agreement to, among other things, grant liens, incur debt, dispose of assets, make loans and investments, make acquisitions, make certain restricted payments, merge or consolidate, change their business and accounting or reporting practices, in each case subject to customary exceptions for a credit facility of this size and type . As of March 31, 2016 the Company was in compliance with the covenants of the Amended Debt Agreement.  The Amended Debt Agreement includes certain customary events of default that include, among other things, non-payment of principal, interest or fees; inaccuracy of representations and warranties; violation of covenants; cross-default on certain other indebtedness; bankruptcy and insolvency; and change of control. Upon the occurrence and during the continuance of an event of default, the lenders may declare all outstanding principal and accrued but unpaid interest under the Amended Debt Agreement immediately due and payable , and may exercise the other rights and remedies provided for under the Amended Debt Agreement and related loan documents.  The short-term and long-term balances of the Company’s term loan are as follows (in thousands):    Three Months Ended  March 31,  2016 2015  Term loan balance $ 75,000 $ --  Less unamortized loan origination costs (2,429) --  Total borrowed 72,571 --  Less short-term loan balance (1,330) --  Long-term loan balance $ 71,241 $ --  Interest Expense  Interest expense was $ 717,000 and $ 30,000 for the three months ended March 31, 2016 and 2015 , respectively . Interest expense in both periods included interest on debt and uncertain tax positions. 

Commitments And Contingencies

Commitments And Contingencies	3 Months Ended
	Mar. 31, 2016
Commitments And Contingencies [Abstract]
Commitments And Contingencies	12. Commitments and Contingencies Liability Claims The Company’s estimated unreported loss liability was $1.6 million and $1.4 million as of March 31, 2016 and December 31, 2015 , respectively. As of March 31, 2016 and December 31, 2015 , the related recoverable insurance amounts were $613,000 and $600,000 , respectively. The Company accrues its estimate of unreported product and tissue processing liability claims as a component of other long ‑term liabilities and records the related recoverable insurance amount as a component of other long ‑term assets, as appropriate. Further analysis indicated that the liability as of March 31, 2016 could have been estimated to be as high as $3.0 million, after including a reasonable margin for statistical fluctuations calculated based on actuarial simulation techniques.  Employment Agreements  The employment agreement of the Company’s Chairman, President, and Chief Executive Officer (“CEO”), Mr. J. Patrick Mackin, provides for a severance payment, which would become payable upon the occurrence of certain employment termination events, including termination by the Company without cause.  The employment agreement of the Company’s former President, CEO, and Executive Chairman, Mr. Steven G. Anderson, conferred certain benefits on Mr. Anderson upon his retirement or termination of employment in conjunction with certain change in control events. On April 9, 2015 Mr. Anderson retired from service as an employee of the Company and Chair of its Board of Directors, and entered into a separation agreement with the Company. The Company recorded expense of approximately $1.4 million related to Mr. Anderson’s separation agreement in the second quarter of 2015. The Company had remaining obligations due under Mr. Anderson’s separation agreement of $93,000 and $195,000 as of March 31, 2016 and December 31, 2015 , respectively.  PerClot Technology  On September 28, 2010 the Company entered into a worldwide distribution agreement (the “Distribution Agreement”) and a license and manufacturing agreement (the “License Agreement”) with Starch Medical, Inc. (“ SMI”), for PerClot, a polysaccharide hemostatic agent used in surgery. The Distribution Agreement has a term of 15 years, but can be terminated for any reason before the expiration date by CryoLife by providing 180 days’ notice. The Distribution Agreement also contains minimum purchase requirements that expire upon the termination of the Distribution Agreement or following U.S. regulatory approval for PerClot. Separate and apart from the terms of the Distribution Agreement, pursuant to the License Agreement, as amended by a September 2, 2011 Technology Transfer Agreement, CryoLife can manufacture and sell PerClot, assuming appropriate regulatory approvals, in the U.S. and certain other jurisdictions and may be required to pay royalties to SMI at certain rates on net revenues of products.  CryoLife paid $500,000 to SMI in January 2015 related to the achievement of a contingent milestone. The Company may make additional contingent payments to SMI of up to $1.0 million if certain U.S. regulatory and certain commercial milestones are achieved.  The Company is conducting its pivotal clinical trial to gain approval to commercialize PerClot for surgical indications in the U.S. The Company began enrollment in the trial in the second quarter of 2015 but later suspended enrollment pending consultation with the FDA regarding the trial protocol. Discussions with the FDA are ongoing and depending on the outcome of these discussions and the Company’s final decision concerning resumption of the trial, the Company could receive Premarket Approval (“PMA”) from the FDA in 2019.  As of March 31, 2016 the Company had $1.5 million in prepaid royalties and $3.1 million in net intangible assets on the Company’s Summary Consolidated Balance Sheets related to the PerClot product line. If the Company does not ultimately pursue or receive FDA approval to commercialize PerClot in the U.S. these assets could be materially impaired in future periods.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2016
Shareholders' Equity [Abstract]
Shareholders' Equity	13. Shareholders’ Equity Cash Dividends The Company initiated a cash dividend in the third quarter of 2012 and paid the dividend quarterly until the Company’s Board of Directors discontinued dividend payments for the foreseeable future in December 2015. The Company paid dividend payments of $850,000 for the three months ended March 31, 2015 from cash on hand. The dividend payments were recorded as a reduction to retained earnings on the Company’s Summary Consolidated Balance Sheets.  Common Shares Issued  In January 2016 the Company issued 3,703,699 shares of CryoLife common stock, as part of the consideration for the acquisition of On-X. The stock had a value of $34.6 million as determined on the date of the closing. See Note 4 for further discussion of the On-X acquisition.

Stock Compensation

Stock Compensation	3 Months Ended
	Mar. 31, 2016
Stock Compensation [Abstract]
Stock Compensation	14. Stock Compensation Overview  The Company has stock option and stock incentive plans for employees and non-employee Directors that provide for grants of restricted stock awards (“RSAs”), performance stock awards (“PSAs”), restricted stock units (“RSUs”), performance stock units (“PSUs”), and options to purchase shares of Company common stock at exercise prices generally equal to the fair values of such stock at the dates of grant. The Company also maintains a shareholder-approved Employee Stock Purchase Plan (the “ESPP”) for the benefit of its employees. The ESPP allows eligible employees to purchase common stock on a regular basis at the lower of 85 % of the market price at the beginning or end of each offering period. Equity Grants During the three months ended March 31, 2016 the Compensation Committee of the Company’s Board of Directors (the “Committee”) authorized awards from approved stock incentive plans of RSAs and PSUs to certain Company officers, which, assuming that performance under the PSUs were to be achieved at target levels, together totaled 277,000 shares and had an aggregate grant date market value of $ 2.8 million. The PSUs granted in 2016 represent the right to receive from 60 % to 150 % of the target number of shares of common stock. The performance component of PSU awards granted in 2016 was based on attaining specified levels of adjusted EBITDA, adjusted inventory levels, and trade accounts receivable days sales outstanding, each as defined in the PSU grant documents, for the 2016 calendar year. The Company currently believes that achievement of the performance component is probable, and it will reevaluate this likelihood on a quarterly basis.  During the three months ended March 31, 2015 the Committee authorized awards from approved stock incentive plans of RSUs to certain employees and RSAs and PSUs to certain Company officers, which, counting PSUs at target levels, together totaled 276,000 shares of common stock and had an aggregate grant date market value of $ 3.0 million . The PSUs granted in 2015 represented the right to receive from 60% to 150% of the target number of shares of common stock. The performance component of PSU awards granted in 2015 was based on attaining specified levels of adjusted EBITDA, as defined in the PSU grant documents, for the 2015 calendar year. The PSUs granted in 2015 earned 127% of the target number of shares. The Committee authorized, from approved stock incentive plans, grants of stock options to purchase a total of 384,000 and 283,000 shares to certain Company officers during the three months ended March 31, 2016 and 2015 , respectively. The exercise prices of the options were equal to the closing stock prices on their respective grant dates.  Employees purchased common stock totaling 38,000 and 36,000 shares in the three months ended March 31, 2016 and 2015 , respectively, through the ESPP.  Stock Compensation Expense The following weighted ‑average assumptions were used to determine the fair value of options:    Three Months Ended Three Months Ended  March 31, 2016 March 31, 2015  Stock Options ESPP Options Stock Options ESPP Options  Expected life of options 4.75 Years .50 Years 4.75 Years .50 Years  Expected stock price volatility 0.40 0.30 0.45 0.34  Dividends 0.00% 0.00% 1.09% 1.06%  Risk-free interest rate 1.20% 0.49% 1.51% 0.12%   The following table summarizes total stock compensation expenses prior to the capitalization of amounts into deferred preservation and inventory costs (in thousands):    Three Months Ended  March 31,  2016 2015  RSA, PSA, RSU, and PSU expense $ 1,088 $ 865  Stock option and ESPP option expense 382 308  Total stock compensation expense $ 1,470 $ 1,173 Included in the total stock compensation expense, as applicable in each period, were expenses related to RSAs, PSAs, RSUs, PSUs, and stock options issued in each respective year, as well as those issued in prior periods that continue to vest during the period, and compensation related to the ESPP. These amounts were recorded as stock compensation expense and were subject to the Company’s normal allocation of expenses to inventory costs and deferred preservation costs. The Company capitalized $ 57,000 and $36,000 in the three months ended March 31, 2016 and 2015 , respectively, of the stock compensation expense into its inventory costs and deferred preservation costs.  As of March 31, 2016 the Company had total unrecognized compensation costs of $ 6.0 million related to RSAs, PSAs, RSUs, and PSUs and $2.9 million related to unvested stock options, before considering the effect of expected forfeitures. As of March 31, 2016 this expense is expected to be recognized over a weighted-average period of 2.2 years for stock options, 1.8 years for RSAs, 1.7 years for RSUs, 1.5 years for PSUs, and 1.4 years for PSAs.

Income Per Common Share

Income Per Common Share	3 Months Ended
	Mar. 31, 2016
Income Per Common Share [Abstract]
Income Per Common Share	15. Income Per Common Share The following table sets forth the computation of basic and diluted income per common share (in thousands, except per share data):    Three Months Ended  March 31,  Basic income (loss) per common share 2016 2015  Net income (loss) $ 2,541 $ (274)  Net (income) loss allocated to participating securities (48) 7  Net income (loss) allocated to common shareholders $ 2,493 $ (267)   Basic weighted-average common shares outstanding 31,029 27,523  Basic income (loss) per common share $ 0.08 $ (0.01)   Three Months Ended  March 31,  Diluted income (loss) per common share 2016 2015  Net income (loss) $ 2,541 $ (274)  Net (income) loss allocated to participating securities (47) 7  Net income (loss) allocated to common shareholders $ 2,494 $ (267)   Basic weighted-average common shares outstanding 31,029 27,523  Effect of dilutive stock options and awards a 742 --  Diluted weighted-average common shares outstanding 31,771 27,523  Diluted income (loss) per common share $ 0.08 $ (0.01) ___________________ a The Company excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares because the inclusion of these stock options would be antidilutive to income (loss) per common share. The Company also excluded common stock equivalents from stock awards from the calculation of diluted weighted-average common shares outstanding during periods of net losses because the inclusion of these stock options would be antidilutive to income (loss) per common share. Accordingly, stock options to purchase a weighted-average 838,000 shares for the three months ended March 31, 2016 , and 1.2 million shares for the three months ended March 31, 2015 were excluded from the calculation of diluted weighted-average common shares outstanding. Additionally the Company excluded a weighted-average 399,000 shares of common stock equivalents for outstanding stock awards in the quarter ended March 31, 2015.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2016
Segment Information [Abstract]
Segment Information	16. Segment Information The Company has two reportable segments organized according to its products and services: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue ® Surgical Adhesive; BioFoam ® Surgical Matrix; On-X products, since the acquisition of On-X; CardioGenesis cardiac laser therapy; PerClot; PhotoFix; HeRO Graft; and ProCol, through the date of the ProCol Sale. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. There are no intersegment revenues.  The primary measure of segment performance, as viewed by the Company’s management, is segment gross margin, or net external revenues less cost of products and preservation services. The Company does not segregate assets by segment; therefore, asset information is excluded from the segment disclosures below.  The following table summarizes revenues, cost of products and services, and gross margins for the Company’s operating segments (in thousands):    Three Months Ended  March 31,  2016 2015  Revenues:  Medical devices $ 27,018 $ 19,391  Preservation services 15,998 14,440  Total revenues 43,016 33,831   Cost of products and preservation services:  Medical devices 7,003 5,033  Preservation services 8,392 9,131  Total cost of products and preservation services 15,395 14,164   Gross margin:  Medical devices 20,015 14,358  Preservation services 7,606 5,309  Total gross margin $ 27,621 $ 19,667 The following table summarizes net revenues by product and service (in thousands):     Three Months Ended  March 31,  2016 2015  Products:  BioGlue and BioFoam $ 15,316 $ 14,042  On-X 6,715 --  CardioGenesis cardiac laser therapy 1,984 2,137  PerClot 991 976  PhotoFix 381 172  HeRO Graft 1,413 1,860  ProCol 218 204  Total products 27,018 19,391   Preservation services:  Cardiac tissue 6,428 6,663  Vascular tissue 9,570 7,777  Total preservation services 15,998 14,440   Total revenues $ 43,016 $ 33,831 

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2016
Financial Instruments [Abstract]
Summary Of Financial Instruments Measured At Fair Value	   March 31, 2016 Level 1 Level 2 Level 3 Total  Cash equivalents:  Money market funds $ 714 $ -- $ -- $ 714  Restricted securities:  Money market funds 812 -- -- 812  Total assets $ 1,526 $ -- $ -- $ 1,526      December 31, 2015 Level 1 Level 2 Level 3 Total  Cash equivalents:  Money market funds $ 549 $ -- $ -- $ 549  Restricted securities:  Money market funds 830 -- -- 830  Total assets $ 1,379 $ -- $ -- $ 1,379  

Cash Equivalents And Restrict23

Cash Equivalents And Restricted Cash And Securities (Tables)	3 Months Ended
	Mar. 31, 2016
Cash Equivalents And Restricted Cash And Securities [Abstract]
Summary Of Cash Equivalents And Restricted Cash And Securities	  Unrealized Estimated  Holding Market  March 31, 2016 Cost Basis Gains Value  Cash equivalents:  Money market funds $ 714 $ -- $ 714  Restricted cash and securities:  Money market funds 812 -- 812   Unrealized Estimated  Holding Market  December 31, 2015 Cost Basis Gains Value  Cash equivalents:  Money market funds $ 549 $ -- $ 549  Restricted cash and securities:  Cash 5,000 -- 5,000  Money market funds 830 -- 830 

Acquisition Of On-X Life Tech24

Acquisition Of On-X Life Technologies (Tables)	3 Months Ended
	Mar. 31, 2016
Acquisition of On-X Life Technologies [Abstract]
Preliminary Purchase Price Allocation	  Opening  Balance Sheet  Cash and cash equivalents $ 2,472  Receivables 6,265  Inventories 13,033  Intangible assets 53,950  Goodwill 66,768  Other assets 6,184  Liabilities assumed (20,455)  Total purchase price $ 128,217 
Preliminary Pro Forma Information	  Three Months Ended  March 31,  2016 2015  Total revenues $ 44,643 $ 41,612  Net income 5,661 (12,447)   Pro forma income per common share - basic $ 0.17 $ (0.39)  Pro forma income per common share - diluted $ 0.17 $ (0.39) 

Inventories And Deferred Pres25

Inventories And Deferred Preservation Costs (Tables)	3 Months Ended
	Mar. 31, 2016
Inventories And Deferred Preservation Costs [Abstract]
Schedule Of Inventories	  March 31, December 31,  2016 2015  Raw materials and supplies $ 8,868 $ 8,590  Work-in-process 2,610 633  Finished goods 13,809 5,420  Total inventories $ 25,287 $ 14,643 
Schedule Of Deferred Preservation Costs	  March 31, December 31,  2016 2015  Cardiac tissues $ 13,065 $ 11,722  Vascular tissues 12,937 13,019  Total deferred preservation costs $ 26,002 $ 24,741 

Goodwill And Other Intangible26

Goodwill And Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill And Other Intangible Assets [Abstract]
Schedule Of Carrying Values Of Indefinite Lived Intangible Assets	  March 31, December 31,  2016 2015  Goodwill $ 76,833 $ 11,365  Procurement contracts and agreements 2,013 2,013  Trademarks 839 860 
Schedule Of Goodwill By Reportable Segment	  Medical Devices Segment  Balance as of December 31, 2015 $ 11,365  Goodwill from On-X acquisition 66,768  Goodwill allocated to sale of HeRO Graft product line (1,200)  Goodwill allocated to sale of ProCol distribution rights and purchase option (100)  Balance as of March 31, 2016 $ 76,833 
Schedule Of Gross Carrying Values, Accumulated Amortization, And Approximate Amortization Period Of Definite Lived Intangible Assets	  Gross Carrying Accumulated Amortization  March 31, 2016 Value Amortization Period  Acquired technology $ 36,410 $ 4,296 11 – 22 Years  Customer lists and relationships 29,140 1,092 13 – 22 Years  Distribution and manufacturing rights and know-how 4,059 1,317 11 – 15 Years  Patents 3,775 2,656 17 Years  Non-compete agreement 381 352 10 Years  Other 1,605 335 3 – 5 Years   Gross Carrying Accumulated Amortization  December 31, 2015 Value Amortization Period  Acquired technology $ 14,020 $ 4,954 11 – 16 Years  Patents 4,081 2,664 17 Years  Distribution and manufacturing rights and know-how 4,059 1,245 11 – 15 Years  Customer lists and relationships 3,370 1,054 13 – 17 Years  Non-compete agreement 381 343 10 Years  Other 1,583 210 3 – 5 Years 
Summary Of Amortization Expense	  Three Months Ended  March 31,  2016 2015  Amortization expense $ 962 $ 515 
Scheduled Amortization Of Intangible Assets For Next Five Years	  Remainder  of 2016 2017 2018 2019 2020 2021  Amortization expense $ 3,399 $ 4,487 $ 4,369 $ 3,984 $ 3,812 $ 3,789 

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2016
Debt [Abstract]
Schedule Of Short-Term And Long-Term Balances Of Term Loan	  Three Months Ended  March 31,  2016 2015  Term loan balance $ 75,000 $ --  Less unamortized loan origination costs (2,429) --  Total borrowed 72,571 --  Less short-term loan balance (1,330) --  Long-term loan balance $ 71,241 $ -- 

Stock Compensation (Tables)

Stock Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Stock Compensation [Abstract]
Schedule Of Weighted-Average Assumptions Used To Determine The Fair Value Of Options	  Three Months Ended Three Months Ended  March 31, 2016 March 31, 2015  Stock Options ESPP Options Stock Options ESPP Options  Expected life of options 4.75 Years .50 Years 4.75 Years .50 Years  Expected stock price volatility 0.40 0.30 0.45 0.34  Dividends 0.00% 0.00% 1.09% 1.06%  Risk-free interest rate 1.20% 0.49% 1.51% 0.12%  
Summary Of Total Stock Compensation Expenses	  Three Months Ended  March 31,  2016 2015  RSA, PSA, RSU, and PSU expense $ 1,088 $ 865  Stock option and ESPP option expense 382 308  Total stock compensation expense $ 1,470 $ 1,173 

Income Per Common Share (Tables

Income Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2016
Income Per Common Share [Abstract]
Computation Of Basic And Diluted Income Per Common Share	  Three Months Ended  March 31,  Basic income (loss) per common share 2016 2015  Net income (loss) $ 2,541 $ (274)  Net (income) loss allocated to participating securities (48) 7  Net income (loss) allocated to common shareholders $ 2,493 $ (267)   Basic weighted-average common shares outstanding 31,029 27,523  Basic income (loss) per common share $ 0.08 $ (0.01)   Three Months Ended  March 31,  Diluted income (loss) per common share 2016 2015  Net income (loss) $ 2,541 $ (274)  Net (income) loss allocated to participating securities (47) 7  Net income (loss) allocated to common shareholders $ 2,494 $ (267)   Basic weighted-average common shares outstanding 31,029 27,523  Effect of dilutive stock options and awards a 742 --  Diluted weighted-average common shares outstanding 31,771 27,523  Diluted income (loss) per common share $ 0.08 $ (0.01) ___________________ a The Company excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares because the inclusion of these stock options would be antidilutive to income (loss) per common share. The Company also excluded common stock equivalents from stock awards from the calculation of diluted weighted-average common shares outstanding during periods of net losses because the inclusion of these stock options would be antidilutive to income (loss) per common share. Accordingly, stock options to purchase a weighted-average 838,000 shares for the three months ended March 31, 2016 , and 1.2 million shares for the three months ended March 31, 2015 were excluded from the calculation of diluted weighted-average common shares outstanding. Additionally the Company excluded a weighted-average 399,000 shares of common stock equivalents for outstanding stock awards in the quarter ended March 31, 2015.

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2016
Segment Information [Abstract]
Revenues, Cost Of Products And Services, And Gross Margins For Operating Segments	  Three Months Ended  March 31,  2016 2015  Revenues:  Medical devices $ 27,018 $ 19,391  Preservation services 15,998 14,440  Total revenues 43,016 33,831   Cost of products and preservation services:  Medical devices 7,003 5,033  Preservation services 8,392 9,131  Total cost of products and preservation services 15,395 14,164   Gross margin:  Medical devices 20,015 14,358  Preservation services 7,606 5,309  Total gross margin $ 27,621 $ 19,667 
Summary Of Net Revenues By Product And Service	  Three Months Ended  March 31,  2016 2015  Products:  BioGlue and BioFoam $ 15,316 $ 14,042  On-X 6,715 --  CardioGenesis cardiac laser therapy 1,984 2,137  PerClot 991 976  PhotoFix 381 172  HeRO Graft 1,413 1,860  ProCol 218 204  Total products 27,018 19,391   Preservation services:  Cardiac tissue 6,428 6,663  Vascular tissue 9,570 7,777  Total preservation services 15,998 14,440   Total revenues $ 43,016 $ 33,831 

Financial Instruments (Details)

Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$ 1,526	$ 1,379
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	714	549
Restricted securities	812	830
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	1,526	1,379
Level 1 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	714	549
Restricted securities	$ 812	$ 830
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets
Level 2 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Restricted securities
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets
Level 3 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Restricted securities

Cash Equivalents And Restrict32

Cash Equivalents And Restricted Cash And Securities (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and securities	$ 44,827	$ 32,413	$ 37,588	$ 33,375
Gains or losses realized on cash equivalents	$ 0	$ 0
On-X Agreement [Member] | Term Loan [Member] | Amended Debt Agreement [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Credit facility, maturity date	Jan. 20, 2021
Restricted Cash And Securities [Member] | Cash [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and securities			$ 5,000
Gains or losses realized on cash equivalents
Restricted Cash And Securities [Member] | Cash [Member] | No Maturity Date [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and securities			$ 5,000
Restricted Cash And Securities [Member] | Money Market Funds [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and securities	$ 812		$ 830
Gains or losses realized on cash equivalents
Restricted Cash And Securities [Member] | Money Market Funds [Member] | Maturity Date Within Three Months [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and securities	$ 241		$ 595
Restricted Cash And Securities [Member] | Money Market Funds [Member] | Maturity Date Between Three Months And One Year [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and securities	$ 571		$ 235
Restricted Cash And Securities [Member] | Minimum [Member] | Money Market Funds [Member] | Maturity Date Between Three Months And One Year [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and securities, period for maturity date	3 months		3 months
Restricted Cash And Securities [Member] | Maximum [Member] | Money Market Funds [Member] | Maturity Date Within Three Months [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and securities, period for maturity date	3 months		3 months
Restricted Cash And Securities [Member] | Maximum [Member] | Money Market Funds [Member] | Maturity Date Between Three Months And One Year [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and securities, period for maturity date	1 year		1 year

Cash Equivalents And Restrict33

Cash Equivalents And Restricted Cash And Securities (Summary Of Cash Equivalents And Restricted Cash And Securities) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Restricted Cash and Cash Equivalents Items [Line Items]
Cost Basis	$ 44,827	$ 32,413	$ 37,588	$ 33,375
Unrealized Holding Gains	0	$ 0
Cash [Member] | Restricted Cash And Securities [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Cost Basis			$ 5,000
Unrealized Holding Gains
Estimated Market Value			$ 5,000
Money Market Funds [Member] | Cash Equivalents [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Cost Basis	$ 714		$ 549
Unrealized Holding Gains
Estimated Market Value	$ 714		$ 549
Money Market Funds [Member] | Restricted Cash And Securities [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Cost Basis	$ 812		$ 830
Unrealized Holding Gains
Estimated Market Value	$ 812		$ 830

Acquisition Of On-X Life Tech34

Acquisition Of On-X Life Technologies (Narrative) (Details) - On-X Agreement [Member] - USD ($) $ in Thousands	Jan. 20, 2016	Mar. 31, 2016	Dec. 22, 2015
Business Acquisition [Line Items]
Acquisition agreement date		Dec. 22, 2015
Total consideration	$ 128,217
Cash consideration	$ 93,600
Common shares issued	3,703,699
Common stock consideration	$ 34,600
Acquisition effective date		Jan. 20, 2016
Transaction and integration costs		$ 5,500
Scenario, Plan [Member]
Business Acquisition [Line Items]
Total consideration			$ 130,000

Acquisition Of On-X Life Tech35

Acquisition Of On-X Life Technologies (Preliminary Purchase Price Allocation) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Jan. 20, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 76,833		$ 11,365
On-X Agreement [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		$ 2,472
Receivables		6,265
Inventories		13,033
Intangible assets		53,950
Goodwill		66,768
Other assets		6,184
Liabilities assumed		(20,455)
Total purchase price		$ 128,217

Acquisition Of On-X Life Tech36

Acquisition Of On-X Life Technologies (Preliminary Pro Forma Information) (Details) - On-X Agreement [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Business Acquisition [Line Items]
Total revenues	$ 44,643	$ 41,612
Net income	$ 5,661	$ (12,447)
Pro forma income per common share-basic	$ 0.17	$ (0.39)
Pro forma income per common share-diluted	$ 0.17	$ (0.39)
Pro forma tax rate	38.00%	38.00%

Sales Of Business Components (D

Sales Of Business Components (Details) - USD ($)	Mar. 18, 2016	Feb. 03, 2016	Jan. 31, 2015	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of business				$ 19,795,000
Hancock Jaffe Laboratories Inc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Distribution agreement amount of payment	$ 3,400,000		$ 576,000			$ 1,700,000
Additional payments to affiliates				1,200,000	$ 1,200,000
Inventory	1,700,000
HeRO Graft Product Line [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Amount of consideration received from sale of product line		$ 18,500,000
Proceeds from divestiture of business				$ 17,800,000
Maximum duration of manufacting responsiblity per transition supply agreement		6 months
Pre-tax gain (loss) on sale business components		$ 8,800,000
HeRO Graft And ProCol Product Lines [Member] | Maximum [Member] | Revenue [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Concentration percentage					10.00%
HeRO Graft And ProCol Product Lines [Member] | Maximum [Member] | Assets, Total [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Concentration percentage					10.00%
ProCol [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of business	2,000,000
Pre-tax gain (loss) on sale business components	845,000
Remaining prepayments	$ 1,700,000

PhotoFix Distribution Agreeme38

PhotoFix Distribution Agreement (Details) - GBI Agreement [Member] $ in Millions	Apr. 14, 2016USD ($)	Mar. 31, 2016item
Initial term of contract for distribution rights		5 years
Number of contract renewals | item		2
Term of contract renewals		1 year
Acquisition effective date		Apr. 13, 2016
Subsequent Event [Member]
Acquisition of PhotoFix technology | $	$ 2.3

Medafor Matters (Details)

Medafor Matters (Details) - C.R. Bard, Inc. [Member] - USD ($) $ in Thousands, shares in Millions	Oct. 01, 2013	Apr. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Additional payment received from C.R. Bard for acquisition of outstanding shares		$ 891	$ 530	$ 15,400
Shares of Medafor common stock acquired by C.R. Bard	2.4

Inventories And Deferred Pres40

Inventories And Deferred Preservation Costs (Narrative) (Details) $ in Millions	Mar. 31, 2016USD ($)
Consignment inventory	$ 4.7
Domestic [Member]
Consignment inventory percentage	85.00%
Foriegn [Member]
Consignment inventory percentage	15.00%

Inventories And Deferred Pres41

Inventories And Deferred Preservation Costs (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventories And Deferred Preservation Costs [Abstract]
Raw materials and supplies	$ 8,868	$ 8,590
Work-in-process	2,610	633
Finished goods	13,809	5,420
Total inventories	$ 25,287	$ 14,643

Inventories And Deferred Pres42

Inventories And Deferred Preservation Costs (Schedule Of Deferred Preservation Costs) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Inventory [Line Items]
Total deferred preservation costs	$ 26,002	$ 24,741
Cardiac Tissues [Member]
Inventory [Line Items]
Total deferred preservation costs	13,065	11,722
Vascular Tissues [Member]
Inventory [Line Items]
Total deferred preservation costs	$ 12,937	$ 13,019

Goodwill And Other Intangible43

Goodwill And Other Intangible Assets (Schedule Of Carrying Values Of Indefinite Lived Intangible Assets)(Details) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Indefinite-lived Intangible Assets [Line Items]
Goodwill	$ 76,833	$ 11,365
Procurement Contracts And Agreements [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite lived intangible assets	2,013	2,013
Trademarks [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite lived intangible assets	$ 839	$ 860

Goodwill And Other Intangible44

Goodwill And Other Intangible Assets (Schedule Of Goodwill By Reportable Segment) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Goodwill [Line Items]
Balance as of December 31, 2015	$ 11,365
Balance as of March 31, 2016	76,833
Medical Devices Segment [Member]
Goodwill [Line Items]
Balance as of December 31, 2015	11,365
Goodwill from On-X acquisition	66,768
Balance as of March 31, 2016	76,833
HeRO Graft [Member] | Medical Devices Segment [Member]
Goodwill [Line Items]
Goodwill allocated to sale	(1,200)
ProCol [Member] | Medical Devices Segment [Member]
Goodwill [Line Items]
Goodwill allocated to sale	$ (100)

Goodwill And Other Intangible45

Goodwill And Other Intangible Assets (Schedule Of Gross Carrying Values, Accumulated Amortization, And Approximate Amortization Period Of Definite Lived Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 36,410	$ 14,020
Accumulated amortization	4,296	4,954
Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	29,140	3,370
Accumulated amortization	1,092	1,054
Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,059	4,059
Accumulated amortization	1,317	1,245
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	3,775	4,081
Accumulated amortization	2,656	2,664
Non-Compete Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	381	381
Accumulated amortization	352	343
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1,605	1,583
Accumulated amortization	$ 335	$ 210
Minimum [Member] | Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	11 years	11 years
Minimum [Member] | Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	13 years	13 years
Minimum [Member] | Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	11 years	11 years
Minimum [Member] | Other [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	3 years	3 years
Maximum [Member] | Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	22 years	16 years
Maximum [Member] | Customer Lists And Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	22 years	17 years
Maximum [Member] | Distribution And Manufacturing Rights And Know-How [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	15 years	15 years
Maximum [Member] | Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	17 years	17 years
Maximum [Member] | Non-Compete Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	10 years	10 years
Maximum [Member] | Other [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	5 years	5 years

Goodwill And Other Intangible46

Goodwill And Other Intangible Assets (Summary Of Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Goodwill And Other Intangible Assets [Abstract]
Amortization expense	$ 962	$ 515

Goodwill And Other Intangible47

Goodwill And Other Intangible Assets (Scheduled Amortization Of Intangible Assets For Next Five Years) (Details) $ in Thousands	Mar. 31, 2016USD ($)
Goodwill And Other Intangible Assets [Abstract]
Amortization expense, Remainder of 2016	$ 3,399
Amortization expense, 2017	4,487
Amortization expense, 2018	4,369
Amortization expense, 2019	3,984
Amortization expense, 2020	3,812
Amortization expense, 2021	$ 3,789

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Income Taxes [Abstract]
Effective income tax rate	58.00%	85.00%
Valuation allowances against deferred tax assets	$ 2.3		$ 2.1
Net deferred tax asset	$ 1.6		$ 18.2

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Jan. 20, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
Term loan balance	$ 75,000,000
Interest expense	717,000	$ 30,000
GE Credit Agreement [Member]
Line of Credit Facility [Line Items]
Credit facility, aggregate amount	$ 20,000,000
Credit facility, maturity date	Sep. 26, 2019
Credit facility, aggregate interest rate				4.75%
Credit facility, outstanding balance				$ 0
Credit facility, remaining availability				20,000,000
Amended Debt Agreement [Member]
Line of Credit Facility [Line Items]
Credit facility, aggregate interest rate	3.93%
On-X Agreement [Member] | Amended Debt Agreement [Member] | Term Loan [Member]
Line of Credit Facility [Line Items]
Term loan balance	$ 75,000,000
Credit facility, maturity date	Jan. 20, 2021
Minimum [Member] | GE Credit Agreement [Member]
Line of Credit Facility [Line Items]
Credit facility, liquidity requirement after effect to stock repurchase	$ 20,000,000
Credit facility, restriction on cash and cash equivalents				$ 5,000,000
Senior Secured Credit Facility [Member] | On-X Agreement [Member] | Amended Debt Agreement [Member]
Line of Credit Facility [Line Items]
Aggregate principal amount			$ 95,000,000
Credit facility, default interest rate	2.00%
Senior Secured Credit Facility [Member] | Minimum [Member] | On-X Agreement [Member] | Amended Debt Agreement [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility, margin	1.75%
Senior Secured Credit Facility [Member] | Minimum [Member] | On-X Agreement [Member] | Amended Debt Agreement [Member] | LIBOR [Member]
Line of Credit Facility [Line Items]
Credit facility, margin	2.75%
Senior Secured Credit Facility [Member] | Maximum [Member] | On-X Agreement [Member] | Amended Debt Agreement [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility, margin	2.75%
Senior Secured Credit Facility [Member] | Maximum [Member] | On-X Agreement [Member] | Amended Debt Agreement [Member] | LIBOR [Member]
Line of Credit Facility [Line Items]
Credit facility, margin	3.75%
Revolving Credit Facility [Member] | On-X Agreement [Member] | Amended Debt Agreement [Member]
Line of Credit Facility [Line Items]
Credit facility, aggregate amount	$ 20,000,000
Credit facility, commitment fee percentage	0.50%
Letter Of Credit Sub-Facility [Member] | On-X Agreement [Member] | Amended Debt Agreement [Member]
Line of Credit Facility [Line Items]
Credit facility, aggregate amount	$ 4,000,000
Swing-Line Sub-Facility [Member] | On-X Agreement [Member] | Amended Debt Agreement [Member]
Line of Credit Facility [Line Items]
Credit facility, aggregate amount	$ 3,000,000
Swing-Line Sub-Facility [Member] | Minimum [Member] | On-X Agreement [Member] | Amended Debt Agreement [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility, margin	1.75%
Swing-Line Sub-Facility [Member] | Maximum [Member] | On-X Agreement [Member] | Amended Debt Agreement [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Credit facility, margin	2.75%

Debt (Schedule Of Short-Term An

Debt (Schedule Of Short-Term And Long-Term Balances Of Term Loan) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Mar. 31, 2015
Debt [Abstract]
Term loan balance	$ 75,000
Less unamortized loan origination costs	(2,429)
Total borrowed	72,571
Less short-term loan balance	(1,330)
Long-term loan balance	$ 71,241

Commitments And Contingencies (

Commitments And Contingencies (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 31, 2015	Mar. 31, 2016	Jun. 30, 2015	Dec. 31, 2015
Commitments And Contingencies [Line Items]
Unreported loss liability		$ 1,600,000		$ 1,400,000
Recoverable insurance amounts		613,000		600,000
Liability estimated after a reasonable margin for statistical fluctuations		3,000,000
PerClot [Member]
Commitments And Contingencies [Line Items]
Prepaid royalties		1,500,000
Intangible assets, net		3,100,000
Former CEO [Member]
Commitments And Contingencies [Line Items]
Incremental expense related to agreement		$ 93,000	$ 1,400,000	$ 195,000
Starch Technology Purchase [Member]
Commitments And Contingencies [Line Items]
Term of distribution agreement		15 years
Number of notice days		180 days
Expected future contingent payment amounts to be initially recorded as research and development expense		$ 1,000,000
Starch Technology Purchase [Member] | Supplemental Employee Retirement Plan, Defined Benefit [Member]
Commitments And Contingencies [Line Items]
Amount paid related to achievement of contingent milestone	$ 500,000

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($)	Jan. 20, 2016	Mar. 31, 2015
Equity Components [Line Items]
Dividend payment from cash on hand		$ 850,000
On-X Agreement [Member]
Equity Components [Line Items]
Common shares issued	3,703,699
Common stock consideration	$ 34,600,000

Stock Compensation (Narrative)

Stock Compensation (Narrative) (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP, percentage of market price for eligible employees	85.00%
Actual percentage of target number of shares of common stock granted as Performance Stock Units			127.00%
Employees purchased common stock, shares	38	36
Capitalized stock compensation expense	$ 57	$ 36
RSAs, RSUs, And PSUs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized from approved stock incentive plans to certain Company officers, non-employee Directors, and certain eligible employees, shares	277	276
Aggregate market value of shares granted under approved stock incentive plans	$ 2,800	$ 3,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Shares	384	283
Unrecognized compensation costs	$ 2,900
Expected weighted-average period for recognizing the unrecognized compensation costs, in years	2 years 2 months 12 days
RSAs, RSUs, PSUs, And PSAs [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs	$ 6,000
Restricted Stock Awards (RSAs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years	1 year 9 months 18 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years	1 year 8 months 12 days
Performance Stock Units (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years	1 year 6 months
Performance Stock Awards (PSAs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected weighted-average period for recognizing the unrecognized compensation costs, in years	1 year 4 months 24 days
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target number of shares of common stock granted as Performance Stock Units	60.00%	60.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target number of shares of common stock granted as Performance Stock Units	150.00%	150.00%

Stock Compensation (Schedule Of

Stock Compensation (Schedule Of Weighted-Average Assumptions Used To Determine The Fair Value Of Options) (Details)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options	4 years 9 months
Expected stock price volatility	40.00%	45.00%
Dividends	0.00%	1.09%
Risk-free interest rate	1.20%	1.51%
ESPP Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options	6 months
Expected stock price volatility	30.00%	34.00%
Dividends	0.00%	1.06%
Risk-free interest rate	0.49%	0.12%

Stock Compensation (Summary Of

Stock Compensation (Summary Of Total Stock Compensation Expenses) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 1,470	$ 1,173
RSA, PSA, RSU, And PSU Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	1,088	865
Stock Option And ESPP Option Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 382	$ 308

Income Per Common Share (Detail

Income Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended
		Mar. 31, 2016	Mar. 31, 2015
Income Per Common Share [Abstract]
Net income (loss)		$ 2,541	$ (274)
Net (income) loss allocated to participating securities		(48)	7
Net income (loss) allocated to common shareholders		$ 2,493	$ (267)
Basic weighted-average common shares outstanding		31,029	27,523
Basic income (loss) per common share		$ 0.08	$ (0.01)
Net (income) loss allocated to participating securities, diluted		$ (47)	$ 7
Net income (loss) allocated to common shareholders, diluted		$ 2,494	$ (267)
Effect of dilutive stock options and awards	[1]	742
Diluted weighted-average common shares outstanding		31,771	27,523
Diluted income (loss) per common share		$ 0.08	$ (0.01)
Antidilutive securities excluded from computation of earnings per share		838	1,200
[1]	The Company excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares because the inclusion of these stock options would be antidilutive to income (loss) per common share. The Company also excluded common stock equivalents from stock awards from the calculation of diluted weighted-average common shares outstanding during periods of net losses because the inclusion of these stock options would be antidilutive to income (loss) per common share. Accordingly, stock options to purchase a weighted-average 838,000 shares for the three months ended March 31, 2016, and 1.2 million shares for the three months ended March 31, 2015 were excluded from the calculation of diluted weighted-average common shares outstanding. Additionally the Company excluded a weighted-average 399,000 shares of common stock equivalents for outstanding stock awards in the quarter ended March 31, 2015.

Segment And Geographic Informat

Segment And Geographic Information (Revenues, Cost Of Products And Services, And Gross Margins For Operating Segments) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)segment	Mar. 31, 2015USD ($)
Number of reportable segments | segment	2
Total revenues	$ 43,016	$ 33,831
Total cost of products and preservation services	15,395	14,164
Total gross margin	27,621	19,667
Operating Segments [Member] | Medical Devices [Member]
Total revenues	27,018	19,391
Total cost of products and preservation services	7,003	5,033
Total gross margin	20,015	14,358
Operating Segments [Member] | Preservation Services [Member]
Total revenues	15,998	14,440
Total cost of products and preservation services	8,392	9,131
Total gross margin	$ 7,606	$ 5,309

Segment And Geographic Inform58

Segment And Geographic Information (Summary Of Net Revenues By Product And Service) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Product Information [Line Items]
Total revenues	$ 43,016	$ 33,831
BioGlue And BioFoam [Member]
Product Information [Line Items]
Total revenues	15,316	14,042
On-X [Member]
Product Information [Line Items]
Total revenues	6,715
CardioGenesis Cardiac Laser Therapy [Member]
Product Information [Line Items]
Total revenues	1,984	2,137
PerClot [Member]
Product Information [Line Items]
Total revenues	991	976
PhotoFix [Member]
Product Information [Line Items]
Total revenues	381	172
HeRO Graft [Member]
Product Information [Line Items]
Total revenues	1,413	1,860
ProCol [Member]
Product Information [Line Items]
Total revenues	218	204
Cardiac Tissue [Member]
Product Information [Line Items]
Total revenues	6,428	6,663
Vascular Tissue [Member]
Product Information [Line Items]
Total revenues	9,570	7,777
Operating Segments [Member] | Total Products [Member]
Product Information [Line Items]
Total revenues	27,018	19,391
Operating Segments [Member] | Total Preservation Services [Member]
Product Information [Line Items]
Total revenues	$ 15,998	$ 14,440